Cardiovascular diseases (CVD) are the number one cause of morbidity and death
worldwide. As estimated by the WHO, the global death rate from CVD is 31% wherein, a …

Venous thrombosis is a leading cause of morbidity and mortality in industrialized countries,
especially in the elderly. Many risk factors have been identified for venous thrombosis that …

The treatment difficulties of venous thrombosis include short half-life, low utilization, and
poor penetration of drugs at thrombus site. Here, we develop one kind of mesoporous …

Deep venous thrombosis (DVT) is one of the most common cardiovascular diseases, but its
pathophysiology remains incompletely understood. Although sterile inflammation has …

Extracellular vesicles (EVs) are well-established mediators of cell-to-cell communication.
EVs can be released by every cell type and they can be classified into three major groups …

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different
cancer types have different rates of thrombosis, with pancreatic cancer having one of the …

Venous thromboembolism is a significant cause of mortality, yet its genetic determinants are
incompletely defined. We performed a discovery genome-wide association study in the …

Deep vein thrombosis (DVT) is a major origin of morbidity and mortality. While DVT has long
been considered as blood coagulation disorder, several recent lines of evidence …

Clinical observations and accumulating laboratory evidence support a complex interplay
between coagulation, inflammation, innate immunity and fibrinolysis in venous …

Injection of recombinant tissue plasminogen activator (rt-PA) is the standard drug treatment
for thrombolysis. However, rt-PA shows risk of hemorrhages and limited efficiency even at …